Mikhail Blagosklonny is an oncology professor at Roswell Park Cancer Institute. He is also a scientist studying cancer and ageing. Mikhail is one of the two editors in chief of the Oncortarget journal. The Oncortarget journal is a peer-reviewed medical journal with a weekly open access and deals with matters concerning oncology. Oncology is a medicinal branch whose concern is to prevent, diagnose and treat cancer. View Mikhail’s profile on Google Scholar
He earned Blagosklonny went to First Pavlov State Medical University of St. Petersburg where he earned his Master’s Degree and PhD in internal medicine and experimental medicine and cardiology respectively. He took a position in Ordway Research Institute as a senior scientist a short time after he was appointed at New York Medical College as an associate professor of medicine in 2002. Mikhail Blagosklonny remained in this position until 2009. It is in 2009 when he was appointed at Roswell Park Centre as professor of oncology.
Through his research, Mikhail believed that cancer and aging involved TOR signaling which is the central regulator of cell metabolism. Certain drugs such as rapamycin could very well treat aging and could extend a person’s life. During these treatments, the healthy cells would not be damaged while attacking the cancer cells. This method would be tested further in animal lab reports on tumor suppressors, apoptosis, cell cycle, mitosis, signal transduction, and anticancer strategies.
Mikhail Blagosklonny has proposed the use of rapamycin, a drug used for the treatment of cancer, as a possible life extension treatment in his formulated hypothesis about the possible role of TOR signalling in aging and cancer. Follow Mikhail on Loop